Search Results

Veru Inc. announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru’s Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am – 11:25 am ET.

Veru Inc. announced that its Annual Meeting of Shareholders scheduled for today was convened and adjourned without any business being conducted due to lack of a required quorum.

Veru Inc. announced that the Company will present two presentations at the American Diabetes Association’s 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

Veru Inc. (NASDAQ: VERU) today announced data from two late-breaker presentations at the American Diabetes Association’s 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.

Veru Inc. today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA.

Veru Inc., a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would like to remind shareholders to vote in connection with the Company’s upcoming annual meeting of shareholders, to be held on Tuesday, June 18, 2024, at 9:00 AM ET.

Veru Inc. (NASDAQ: VERU) today announced that the Company will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.

Veru Inc. announced financial results for its fiscal 2024 second quarter and provided a business update.

Veru Inc. announced that it is rescheduling its 2024 Annual Meeting of Shareholders originally scheduled to be held on March 26, 2024.